Now Reading
India Delays COVID Vaccine Supplies to WHO-Backed COVAX, Sources Say

India Delays COVID Vaccine Supplies to WHO-Backed COVAX, Sources Say

A healthcare worker fills a syringe with a dose of Bharat Biotech’s Covaxin, AIIMS Delhi, January 16, 2021. Photo: Reuters/Adnan Abidi

New Delhi: India has delayed committing supplies of vaccine to the COVAX global sharing platform, two sources told Reuters on Tuesday, a day after one of its key backers, the WHO, said the agency could not “cut corners” to approve a domestically developed vaccine.

The world’s biggest vaccine maker resumed exports of COVID-19 doses this month for the first time since April. It has sent about 4 million to countries such as neighbouring Bangladesh and Iran, but none to COVAX.

On Monday, in the run-up to an October 26 meeting on Covaxin, India’s first domestically developed COIVD-19 vaccine, the World Health Organisation (WHO) said it could not “cut corners” in the approval decision.

One of the sources said it was “frustrating” that India had yet to confirm any supply to COVAX, despite a promise last month by the health minister to meet the commitment, among others, during the quarter to December.

The sources, who have been briefed on the export talks, declined to be identified as they were not authorised to speak on the subject.

Serum Institute of India (SII), the world’s biggest vaccine manufacturer, has contracts to supply hundreds of millions of doses of a licensed version of the AstraZeneca vaccine to COVAX and countries such as Bangladesh.

Its output of the vaccine has more than tripled since April, to reach 220 million doses a month now.

Also read: WHO to Meet on October 26 to Consider ‘Emergency Use’ Listing for Covaxin

India’s health ministry, SII and COVAX co-leads, the WHO and GAVI, did not respond to requests for comment.

Delayed supplies to COVAX could disrupt inoculation drives in many African nations that rely on it for vaccine supplies.

Indian government officials have said they are confident the WHO will soon approve an emergency-use listing for Covaxin, which makes up 11% of the 990 million vaccine doses given in India, with the rest mostly from AstraZeneca.

A few weeks ago, Adar Poonawalla, the chief executive of SII, told the Telegraph newspaper that his company would recommence exports to COVAX in October.

“Initially these supplies will be small, but by January 2022, once we have satisfied domestic demands … we will see large volumes go to COVAX,” he added.

Before India halted overseas vaccine shipments in April so as to meet domestic demand, it donated or sold more than 66 million COVID-19 doses, including Covaxin.

(Reuters – reporting by Krishna N. Das; additional reporting by Sanjeev Miglani; editing by Clarence Fernandez)

Scroll To Top